Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Multicenter, Randomized Controlled Phase 4 Trial Evaluating the Efficacy and Safety of Vespireit, Prolonged-release Tablets (Valenta Pharm JSC, Russia) Versus Arlevert, Tablets (Menarini International Operations Luxembourg S.A., Luxembourg) in Patients With Autonomic Dysfunction Syndrome Accompanied by Functional Vertigo.

NCT06321341 is registered in ClinicalTrials.gov with Valenta Pharm JSC as lead sponsor.

NCT NCT06321341
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06321341 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Multicenter, Randomized Controlled Phase 4 Trial Evaluating the Efficacy and Safety of Vespireit, Prolonged-release Tablets (Valenta Pharm JSC, Russia) Versus Arlevert, Tablets (Menarini International Operations Luxembourg S.A., Luxembourg) in Patients With Autonomic Dysfunction Syndrome Accompanied by Functional Vertigo.
Lead sponsor
Valenta Pharm JSC
Phase
Phase 4
Overall status
Recruiting
Start date
January 24, 2024
Completion date
December 31, 2026
Enrollment
160 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

autonomic dysfunction, vertigo